PA
Profund Advisors Portfolio holdings
AUM
$2.78B
1-Year Return
29.53%
This Quarter Return
-3.96%
1 Year Return
+29.53%
3 Year Return
+153.44%
5 Year Return
+262.59%
10 Year Return
+738.89%
AUM
$2.3B
AUM Growth
-$438M
(-16%)
Cap. Flow
-$251M
Cap. Flow
% of AUM
-10.88%
Top 10 Holdings %
Top 10 Hldgs %
35.75%
Holding
1,125
New
22
Increased
279
Reduced
683
Closed
141
Top Buys
| 1 |
DoorDash
DASH
|
+$1.58M |
| 2 |
Arista Networks
ANET
|
+$1.41M |
| 3 |
TSMC
TSM
|
+$1.39M |
| 4 |
Salesforce
CRM
|
+$1.34M |
| 5 |
JD.com
JD
|
+$1.26M |
Top Sells
| 1 |
NVIDIA
NVDA
|
+$34.4M |
| 2 |
Apple
AAPL
|
+$16.5M |
| 3 |
Microsoft
MSFT
|
+$13.2M |
| 4 |
Broadcom
AVGO
|
+$12.7M |
| 5 |
Amazon
AMZN
|
+$7.27M |
Sector Composition
| 1 | Technology | 41.42% |
| 2 | Consumer Discretionary | 11.82% |
| 3 | Communication Services | 10.93% |
| 4 | Healthcare | 10.6% |
| 5 | Financials | 6.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
951
Cushman & Wakefield
CWK
$3.69B
| $103K | ﹤0.01% |
10,127
-3,334
| -25% | -$34.1K |
|
952
MindMed
MNMD
$726M
| $102K | ﹤0.01% |
17,509
+5,216
| +42% | +$30.5K |
|
|
EXK
953
Endeavour Silver
EXK
$1.71B
| $96.5K | ﹤0.01% |
22,609
+6,179
| +38% | +$26.4K |
|
954
Gerdau
GGB
$6.25B
| $93.7K | ﹤0.01% |
33,003
+6,664
| +25% | +$18.9K |
|
955
Hanesbrands
HBI
$2.23B
| $93.1K | ﹤0.01% |
16,131
-3,495
| -18% | -$20.2K |
|
956
Omeros
OMER
$286M
| $93K | ﹤0.01% |
+11,308
| New | +$93K |
|
957
Medical Properties Trust
MPW
$2.73B
| $92.7K | ﹤0.01% |
15,371
-6,366
| -29% | -$38.4K |
|
958
Oric Pharmaceuticals
ORIC
$1.07B
| $91.9K | ﹤0.01% |
16,469
+5,651
| +52% | +$31.5K |
|
959
Payoneer
PAYO
$2.42B
| $90.2K | ﹤0.01% |
12,333
-1,999
| -14% | -$14.6K |
|
960
Cullinan Oncology
CGEM
$414M
| $89.7K | ﹤0.01% |
11,846
-5,773
| -33% | -$43.7K |
|
961
Lufax Holding
LU
$2.59B
| $87.6K | ﹤0.01% |
29,489
+2,682
| +10% | +$7.97K |
|
962
CleanSpark
CLSK
$2.61B
| $87.6K | ﹤0.01% |
+13,031
| New | +$87.6K |
|
963
Akebia Therapeutics
AKBA
$801M
| $86.3K | ﹤0.01% |
44,922
+7,252
| +19% | +$13.9K |
|
964
Cleveland-Cliffs
CLF
$5.29B
| $86.1K | ﹤0.01% |
10,475
-597
| -5% | -$4.91K |
|
965
Stoke Therapeutics
STOK
$1.18B
| $85.7K | ﹤0.01% |
12,882
-266
| -2% | -$1.77K |
|
966
CEMIG Preferred Shares
CIG
$5.75B
| $83K | ﹤0.01% |
47,139
+10,981
| +30% | +$19.3K |
|
967
CorMedix
CRMD
$1.03B
| $76.9K | ﹤0.01% |
12,480
-5,498
| -31% | -$33.9K |
|
968
NovaGold Resources
NG
$2.75B
| $74.7K | ﹤0.01% |
+25,584
| New | +$74.7K |
|
969
Esperion Therapeutics
ESPR
$506M
| $73.6K | ﹤0.01% |
51,113
+5,429
| +12% | +$7.82K |
|
970
RLX Technology
RLX
$3.3B
| $71.5K | ﹤0.01% |
38,021
+2,533
| +7% | +$4.76K |
|
971
Nuvation Bio
NUVB
$1.13B
| $71.2K | ﹤0.01% |
40,474
+9,195
| +29% | +$16.2K |
|
972
Sana Biotechnology
SANA
$762M
| $69K | ﹤0.01% |
41,082
-19,494
| -32% | -$32.8K |
|
973
EyePoint Pharmaceuticals
EYPT
$973M
| $67.3K | ﹤0.01% |
12,425
-1,321
| -10% | -$7.16K |
|
974
Arbutus Biopharma
ABUS
$780M
| $66.7K | ﹤0.01% |
19,115
-11,113
| -37% | -$38.8K |
|
975
Newell Brands
NWL
$2.62B
| $66K | ﹤0.01% |
10,650
-4,411
| -29% | -$27.3K |
|